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SCIENTIFIC OPINION 
Scientific Opinion on an application by Syngenta (EFSA-GMO-DE-2009-
66) for placing on the market of herbicide tolerant and insect resistant 
maize Bt11 × MIR162 × MIR604 × GA21 and subcombinations 
independently of their origin for food and feed uses, import and processing 
under Regulation (EC) No 1829/2003
1
 
EFSA Panel on Genetically Modified Organisms (GMO)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The EFSA GMO Panel previously assessed the four single events combined to produce a four-event 
stack maize Bt11 × MIR162 × MIR604 × GA21 and did not identify safety concerns. In this opinion, 
the EFSA GMO Panel assesses the four-event stack maize and all its subcombinations independently 
of their origin. No new data on the single events, leading to modification of the original conclusions 
on their safety, were identified. The molecular, agronomic, phenotypic and compositional data on the 
four-event stack maize did not give rise to safety concerns and there is no reason to expect interactions 
between the single events impacting on the food and feed safety of the four-event stack maize. 
Considering the routes of exposure and limited exposure levels, the Panel concludes that this four-
event stack maize would not raise safety concerns in the event of accidental release of viable grains 
into the environment. The EFSA GMO Panel concludes that the four-event stack maize is as safe and 
as nutritious as its conventional counterpart in the context of its scope. Among the 10 
subcombinations, four have been assessed previously and no safety concerns were identified. For the 
remaining six subcombinations, the EFSA GMO Panel followed a weight-of-evidence approach, and 
concluded they are expected to be as safe as the four-event stack maize. For some subcombinations 
that could be produced by conventional crossing through targeted breeding approaches, little or no 
specific data were submitted, giving rise to uncertainties due to data gaps. To reduce these 
uncertainties and to confirm assumptions made for the assessment of these subcombinations, the 
EFSA GMO Panel recommends that the applicant collate relevant information, if these 
subcombinations were to be created via targeted breeding approaches and commercialised in the 
future. In this case, this information should focus on expression levels of the newly expressed proteins. 
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SUMMARY 
Following the submission of application EFSA-GMO-DE-2009-66 under Regulation (EC) 
No 1829/2003
4
 from Syngenta, the Panel on Genetically Modified Organisms of the European Food 
Safety Authority (referred to hereafter as EFSA GMO Panel) was asked to deliver a scientific opinion 
on the safety of herbicide tolerant and insect resistant genetically modified maize 
Bt11 × MIR162 × MIR604 × GA21 (referred to hereafter as ‘four-event stack maize’) and on all its 
subcombinations
5
 (referred to as ‘subcombinations independently of their origin’ in the Commission 
implementing regulation (EU) No 503/2013)
6
. The scope of application EFSA-GMO-DE-2009-66 is 
for food and feed uses, import and processing, but excludes cultivation within the European Union 
(EU). 
The term ‘subcombination’ refers to any combination of up to three of the events present in the four-
event stack maize Bt11 × MIR162 × MIR604 × GA21. Subcombinations occur as segregating progeny 
in the harvested grains of Bt11 × MIR162 × MIR604 × GA21 (embryo and albumen), and their safety 
is evaluated within the assessment of the four-event stack maize Bt11 × MIR162 × MIR604 × GA21 
in Section 4 of the present opinion. 
‘Subcombination’ also refers to any combination of up to three of the events Bt11, MIR162, MIR604 
or GA21 that has either been or could be produced by conventional crossing, through targeted 
breeding approaches (EFSA GMO Panel, 2011a).These are maize stacks that can be bred, produced 
and marketed independently of the four-event stack Bt11 × MIR162 × MIR604 × GA21. These stacks, 
including their segregating progeny, are risk assessed in the Section 5 of the present opinion. 
In accordance with the EFSA GMO Panel guidance document applicable to this application (EFSA, 
2007a), “where all single events have been assessed, the risk assessment of stacked events should 
focus mainly on issues related to a) stability, b) expression of the events and c) potential interactions 
between the events”. For application EFSA-GMO-DE-2009-66, previous assessments of the four 
single events (Bt11, MIR162, MIR604 and GA21) provided a basis to evaluate the four-event stack 
maize and the 10 subcombinations. 
The four-event stack maize Bt11 × MIR162 × MIR604 × GA21 was produced by conventional 
crossing to combine four single maize events. Maize containing the single events, Bt11 (expressing 
Cry1Ab and PAT proteins), MIR162 (expressing Vip3Aa20 and PMI proteins), MIR604 (expressing 
mCry3A and PMI proteins) and GA21 (expressing mEPSPS protein), were assessed previously and no 
concerns were identified. No safety issue was identified by updated bioinformatic analyses, nor 
reported by the applicant concerning the four single maize events, since the publication of the 
scientific opinions. Consequently, the EFSA GMO Panel considers that its previous conclusions on the 
safety of the single maize events remain valid (Section 3). 
For the four-event stack maize, the risk assessment included the molecular characterisation of the 
inserted DNA and the analysis of the proteins’ expression. An evaluation of the comparative analyses 
of compositional, agronomic and phenotypic characteristics was undertaken, and the safety of the 
newly expressed proteins and the whole food/feed was evaluated with respect to potential toxicity, 
allergenicity and nutritional characteristics. Evaluation of environmental impacts and the Post-Market 
Environmental Monitoring (PMEM) plan was also undertaken. 
The molecular data establish that the transformation events stacked in maize 
Bt11 × MIR162 × MIR604 × GA21 have the same molecular properties and characteristics as the 
                                                     
4  Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed. Official Journal of the European Communities, L268, 1–23. 
5 The 10 subcombinations are three-event stacks Bt11 × MIR162 × MIR604, Bt11 × MIR162 × GA21, 
Bt11 × MIR604 × GA21, MIR162 × MIR604 × GA21; and two-event stacks Bt11 × MIR162, Bt11 × MIR604, 
Bt11 × GA21, MIR162 × MIR604, MIR162 × GA21, MIR604 × GA21. 
6  Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically 
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council 
and amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48. 
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single transformation events. Protein expression analyses showed that the levels of the newly 
expressed proteins are similar in the four-event stack and the single events, with the exception of PMI. 
Comparison of the levels of the newly expressed proteins between the four-event stack and the 
respective single events did not reveal an interaction that would affect protein expression level. 
The newly expressed proteins in the four-event stack maize did not raise concerns for human and 
animal health. The compositional data indicate that maize Bt11 × MIR162 × MIR604 × GA21 would 
be expected to deliver the same nutritional characteristics as its conventional counterpart. This was 
confirmed by the results of an animal feeding study in chickens for fattening. 
The EFSA GMO Panel considers that there is no reason to expect interactions that could impact on the 
food and feed safety. No safety concerns are foreseen for any subcombinations of the individual 
events, including those not previously assessed by EFSA. 
Considering the introduced traits, the outcome of the comparative analysis, the routes of exposure and 
the limited exposure levels, the EFSA GMO Panel concluded that this four-event stack maize would 
not raise safety concerns in the event of accidental release of viable GM maize grains into the 
environment, irrespective of possible interactions between the individual events within this four-event 
stack maize. 
In conclusion, the EFSA GMO Panel is of the opinion that the four-event stack maize is as safe and as 
nutritious as its conventional counterpart and commercial maize varieties in the context of its scope. 
Concerning the 10 subcombinations, EFSA GMO Panel previously assessed four of them (i.e. 
Bt11 × GA21, MIR604 × GA21, Bt11 × MIR604, Bt11 × GA21 × MIR604) and did not identify 
safety concerns. No new scientific information regarding these subcombinations was retrieved in a 
literature search covering the period since the publication of the respective scientific opinions. 
Moreover, the additional data available on protein expression, agronomic, phenotypic and 
compositional characteristics of maize Bt11 × MIR604 × GA21 confirmed the result of the previous 
assessment. Consequently, the EFSA GMO Panel considers that its previous conclusions on these four 
subcombinations remain valid. 
For the remaining six subcombinations, with the exception of Bt11 × MIR162 × GA21, the applicant 
provided no experimental data. The EFSA GMO Panel used a weight-of-evidence approach to 
conclude on the safety of these six subcombinations, considering information from: (i) the previous 
assessments of the four single maize events, (ii) the assessment of the four-event stack maize, and (iii) 
the four subcombinations previous assessed and the newly available data. The EFSA GMO Panel is of 
the opinion that the six subcombinations are expected to be as safe as the four-event stack maize. 
The EFSA GMO Panel considers that post-market monitoring of food/feed derived from maize 
Bt11 × MIR162 × MIR604 × GA21 or 10 subcombinations is not necessary, given the absence of 
safety concerns identified. 
The EFSA GMO Panel is of the opinion that the PMEM plans provided by the applicant are in line 
with the scope of the four-event stack maize and the four subcombinations previously assessed. 
However, the PMEM plan submitted by the applicant for the four-event stack maize does not include 
any provision for the six subcombinations that were not previously assessed. Therefore, the EFSA 
GMO Panel recommends the applicant to revise the plan accordingly. 
The EFSA GMO  Panel did not find indication that the subcombinations, resulting from combination 
of any of the single events included in the four-stack, would raise safety concerns. However, for some 
subcombinations (Bt11 x MIR162 x MIR604, MIR162 x MIR604 x GA21, Bt11 x MIR162, MIR162 
x MIR604, MIR162 x GA21) that could be produced by conventional crossing through targeted 
breeding approaches, little or no specific data were submitted.  For these the EFSA GMO Panel has 
drawn conclusions on a weight-of-evidence approach, giving rise to uncertainties due to data gaps.  
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In order to reduce these uncertainties and to confirm assumptions made for the assessment of these 
subcombinations, the EFSA GMO Panel recommends that the applicant collate relevant information, if 
these subcombinations were to be created via targeted breeding approaches and commercialised in the 
future. In this case, this information should focus on expression levels of the newly expressed proteins. 
In delivering its scientific opinion, the EFSA GMO Panel considered the data available on the four-
event stack maize and the subcombinations, the scientific comments submitted by the Member States 
and the relevant scientific publications. 
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BACKGROUND 
On 4 March 2009, the European Food Safety Authority (EFSA) received from the Competent 
Authority of Germany application EFSA-GMO-DE-2009-66, for authorisation of genetically modified 
(GM) maize Bt11 × MIR162 × MIR604 × GA21 submitted by Syngenta within the framework of 
Regulation (EC) No 1829/2003 on genetically modified food and feed for food and feed uses, import 
and processing (EC, 2003). 
After receiving the application EFSA-GMO-DE-2009-66 and in accordance with Articles 5(2)(b) and 
17(2)(b) of Regulation (EC) No 1829/2003, EFSA informed Member States and the European 
Commission, and made the summary of the application available to the public on the EFSA website
7
. 
EFSA initiated a formal review of the application to check compliance with the requirements laid 
down in Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. On 19 May 2009, 12 and 
24 June 2009, EFSA received additional information (requested on 27 March 2009 and 3 June 2009, 
respectively). On 13 July 2009, EFSA declared the application valid in accordance with Articles 6(1) 
and 18(1) of Regulation (EC) No 1829/2003. 
EFSA made the valid application available to Member States and the European Commission, and 
consulted nominated risk assessment bodies of Member States, including national Competent 
Authorities within the meaning of Directive 2001/18/EC
8
 following the requirements of Articles 6(4) 
and 18(4) of Regulation (EC) No 1829/2003 (EC, 2001, 2003), to request their scientific opinion. 
Member States had three months after the date of receipt of the valid application (until 
22 October 2009) to make their opinion known. 
The scope defined by the applicant at the time of submission was “all food and feed products 
containing, consisting or produced from Bt11 x MIR162 x MIR604 x GA21 maize including products 
from inbreds and hybrids obtained by conventional breeding of this stacked maize product. The 
application also covers the import and industrial processing of Bt11 x MIR162 x MIR604 x GA21 
maize for all potential uses as any other maize.” After clarifications (letters received on 14 June 2010, 
15 September 2010, 15 March 2012, 6 June 2012, 8 July 2013 and 24 July 2013), the applicant 
notified EFSA that the scope of EFSA-GMO-DE-2009-66 was to “include Bt11 x MIR 162 x MIR604 
x GA21 maize and all subcombinations from Bt11 x MIR 162 x MIR604 x GA21 maize independently 
of their origin.” 
The EFSA GMO Panel carried out an evaluation of the scientific risk assessment of maize 
Bt11 × MIR162 × MIR604 × GA21 and all its subcombinations. On 21 September 2009, 
5 February 2010, 17 March 2010, 21 January 2011, 6 July 2012, 7 December 2012, 5 February 2013, 
5 February 2014, 13 March 2014, 9 September 2014, 16 September 2014, 24 October 2014 and 
18 September 2015, the EFSA GMO Panel requested additional information from the applicants. The 
applicants provided the requested information on 21 December 2009, 5 October 2010, 3 June 2010, 
1 February 2012, 10 October 2012, 19 March 2013, 25 March 2013, 18 February 2014, 16 June 2014, 
25 September 2014, 15 October 2014, 3 July 2015 and 24 September 2015, respectively. EFSA 
received additional information submitted by the applicant spontaneously on 10 December 2013, 
28 July 2014, 21 July 2015 and 10 August 2015. 
In giving its scientific opinion to the European Commission, the Member States and the applicant, and 
in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003 (EC, 2003), EFSA has 
endeavoured to respect a time limit of six months from the acknowledgement of the valid application. 
As additional information was requested by the EFSA GMO Panel, the time limit of six months was 
extended accordingly, in line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) 
No 1829/2003. 
                                                     
7 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2009-00444  
8 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the 
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.03.2001, 
p 1-38. 
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According to Regulation (EC) No 1829/2003 (EC, 2003), this scientific opinion is to be seen as the 
report requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA 
overall opinion in accordance with Articles 6(5) and 18(5). 
TERMS OF REFERENCE 
The EFSA GMO Panel was requested to carry out a scientific risk assessment of “maize Bt11 x 
MIR162 x MIR604 x GA21 and all the possible subcombinations of the single events, independently of 
their origin” for food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) 
of Regulation (EC) No 1829/2003. 
Where applicable, any conditions or restrictions which should be imposed on the placing on the 
market and/or specific conditions or restrictions for use and handling, including post-market 
monitoring requirements based on the outcome of the risk assessment and, in the case of GMOs or 
food/feed containing or consisting of GMOs, conditions for the protection of particular 
ecosystems/environment and/or geographical areas should be indicated in accordance with Articles 
6(5)(e) and 18(5)(e) of Regulation (EC) No 1829/2003. 
The EFSA GMO Panel was not requested to give an opinion on information required under Annex II 
to the Cartagena Protocol. Furthermore, the EFSA GMO Panel did not consider proposals for labelling 
and methods of detection (including sampling and the identification of the specific transformation 
event in the food/feed and/or food/feed produced from it), which are matters related to risk 
management. 
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ASSESSMENT 
1. Introduction 
Application EFSA-GMO-DE-2009-66 covers 11 maize stacks: the four-event stack maize 
Bt11 × MIR162 × MIR604 × GA21 and the 10 subcombinations independently of their origin 
resulting from the combination of any of the single events Bt11, MIR162, MIR604 and GA21 
(Table 1). The scope of this application is for food and feed uses, import and processing, but excludes 
cultivation within the European Union (EU). 
The term ‘subcombination’ refers to any combination of up to three of the events present in the four-
event stack maize Bt11 × MIR162 × MIR604 × GA21. Subcombinations occur as segregating progeny 
in the harvested grains of Bt11 × MIR162 × MIR604 × GA21 (embryo and albumen), and their safety 
is part of the assessment of the four-event stack maize Bt11 × MIR162 × MIR604 × GA21 in 
Section 4 of the present opinion. 
‘Subcombination’ also refers to any combination of up to three of the events Bt11, MIR162, MIR604 
or GA21 that has either been or could be produced by conventional crossing, through targeted 
breeding approaches (EFSA GMO Panel, 2011a). These are maize stacks that can be bred, produced 
and marketed independently of the four-event stack Bt11 × MIR162 × MIR604 × GA21. These stacks, 
including their segregating progeny, are risk assessed in the Section 5 of the present opinion. 
Table 1:  Eleven maize stacks covered by the scope of application EFSA-GMO-DE-2009-66 
Degree of stacking Events Unique identifiers 
Four-event stack 
maize 
Bt11 × MIR162 × MIR604 × GA21 SYN-BTØ11-1 × SYN-IR162-4 × SYN-IR6Ø4-
5 × MON-ØØØ21-9  
Three-event stack 
maize 
Bt11 × MIR162 × MIR604 SYN-BTØ11-1 × SYN-IR162-4 × SYN-IR6Ø4-5 
Bt11 × MIR162 × GA21 SYN-BTØ11-1 × SYN-IR162-4 × MON-ØØØ21-9  
Bt11 × GA21 × MIR604 SYN-BTØ11-1 × MON-ØØØ21-9 × SYN-IR6Ø4-5  
MIR162 × MIR604 × GA21 SYN-IR162-4 × SYN-IR6Ø4-5 × MON-ØØØ21-9  
Two-event stack 
maize 
Bt11 × MIR162 SYN-BTØ11-1 × SYN-IR162-4  
Bt11 × MIR604 SYN-BTØ11-1 × SYN-IR6Ø4-5  
Bt11 × GA21 SYN-BTØ11-1 × MON-ØØØ21-9  
MIR162 × MIR604 SYN-IR162-4 × SYN-IR6Ø4-5  
MIR162 × GA21 SYN-IR162-4 × MON-ØØØ21-9  
MIR604 × GA21 SYN-IR6Ø4-5 × MON-ØØØ21-9  
 
The four-event stack maize was developed to achieve insect resistance and herbicide tolerance to 
glyphosate- and glufosinate ammonium-based herbicides. The insect resistance confers protection 
against specific lepidopteran pests (e.g. Ostrinia nubilalis [European corn borer] and Sesamia 
nonagrioides [Mediterranean corn borer]) and coleopteran pests (Diabrotica spp. [corn rootworm]). 
All four single maize events Bt11, MIR162, MIR604 and GA21 and four of these maize stacks have 
been previously assessed (Table 2) on the basis of experimental data (see Appendix A for complete 
list). No concerns for human and animal health or environmental safety were identified. 
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Table 2:  Single maize events and maize stacks already assessed by the EFSA GMO Panel 
Events Application or mandate Reference 
Bt11 C/F/96/05.10 EFSA (2005) 
EFSA-GMO-RX-Bt11 EFSA (2009a) 
EFSA-M-2012–0232(a)  EFSA GMO Panel (2012b) 
MIR162 EFSA-GMO-DE-2010-82 EFSA GMO Panel (2012a) 
MIR604 EFSA-GMO-UK-2005-11 EFSA (2009b) 
GA21 EFSA-GMO-UK-2005-19 EFSA (2007b) 
EFSA-GMO-RX-GA21 
Bt11 × GA21 EFSA-GMO-UK-2007-49 EFSA GMO Panel (2009) 
MIR604 × GA21 EFSA-GMO-UK-2007-48 EFSA GMO Panel (2010a) 
Bt11 × MIR604 EFSA-GMO-UK-2007-50 EFSA GMO Panel (2010b) 
Bt11 × GA21 × MIR604 EFSA-GMO-UK-2008-56 EFSA GMO Panel (2010c) 
(a): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00713. 
 
The European Food Safety Authority (EFSA) guidance applicable to this application establishes that 
“Where all single events have been assessed, the risk assessment of stacked events should focus mainly 
on issues related to a) stability, b) expression of the events and c) potential interactions between the 
events” (EFSA, 2007a). 
2. Issues raised by Member States 
Issues raised by Member States on maize Bt11 × MIR162 × MIR604 × GA21 were considered in this 
scientific opinion and are addressed in detail in Annex G of the EFSA overall opinion
9
. 
3. Updated information on single events 
Since the publication of the scientific opinions on the single maize events by the EFSA GMO Panel 
(EFSA, 2005, 2007b, 2009a, b; EFSA GMO Panel, 2012a, b), no safety issue pertaining to the four 
single events has been reported by the applicant. 
For events MIR604 and GA21, updated nucleotide sequence information was received
10
. In the case of 
event MIR604, a single nucleotide difference was identified in the non-coding region of the insert as 
compared with the sequence originally reported in 2005. Further analyses demonstrated that this 
nucleotide difference had already been present in the original material used for the risk assessment of 
maize MIR604. In the case of event GA21, new sequence information revealed a nucleotide change in 
the actin promoter of copy 6, a three-base pair deletion contiguous to one nucleotide substitution 
within the 3′ insert flanking region and a difference in the number of complete mepsps (5-enolpyruvyl-
shikimate-3-phosphate synthase) cassettes present within the insert. Similarly to event MIR604, 
further analyses demonstrated that these differences had already been present in the original material 
used for the risk assessment of maize GA21. The EFSA GMO Panel has performed the risk 
assessment of the new sequencing information for events MIR604 and GA21 in the frame of a request 
received from the European Commission
11
 and concluded that the original risk assessments of events 
MIR604 and GA21 as a single and as a part of stacked events remains valid (EFSA GMO Panel, 
2015a, b). 
Bioinformatic analyses on the junction regions for events Bt11, MIR162, MIR604 and GA21, using 
the most up-to-date nucleotide sequences and methodology specified in the 2011 guidance (EFSA 
GMO Panel, 2011a), confirmed that there is no indication of the interruption of a known endogenous 
nuclear genes by any of the inserts
12
. Updated bioinformatic analyses of the amino acid sequence of 
the Open Reading Frames (ORFs) spanning the junction regions revealed no significant similarities to 
                                                     
9 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2009-00444. 
10 Additional information, 21/7/2015, 24/9/2015. 
11 EFSA-Q-2015-00473. 
12 Additional information: 3/7/2015. 
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known toxins or allergens
13
. Similarity searches of the ORFs present within the inserts revealed no 
significant similarities to known toxins. Similarity searches of the ORFs present within the inserts to 
known allergens using the criterion of 35 % identity of the amino acid sequence in a window of 80 
amino acids resulted in the following above-threshold identities. 
3.1. MIR162 
ORF MIR162_Insert_67 shows similarity to Ara h 1 P17 precursor; ORF MIR162_Insert_83 shows 
similarity to wheat high molecular weight (HMW) glutenin, wheat HMW glutenin subunit Ax2*, 
Chain A of Prunus dulcis amandin and to P. dulcis prunin 1 precursor; ORF MIR162_Insert_109 
shows similarity to Chain A of P. dulcis amandin, Jug r 2.0101 and to Juglans regia vicilin-like 
protein precursor. These ORFs are downstream of the ZmUbiInt promoter, but none of them contain a 
start codon in frame, therefore their expression is highly unlikely. ORF MIR162_Insert_342 shows 
similarity to Tri a Triticum aestivum Tri a 31.0101 triosephosphate isomerase. This ORF has a start 
codon; however, it has no promoter and is located on the reverse strand of the insert and, therefore, its 
expression is highly unlikely. 
3.2. MIR604 
ORF MIR604_insert_2014_92 shows similarity to wheat glutenin, peanut Ara h 1 precursor and 
allergen, soybean beta-conglycinin alpha prime subunit and cattle collagen alpha-2(I) chain precursor. 
ORF MIR604_insert_2014_107 shows similarity to wheat glutenin, wheat HMW glutenin 1By9, 5 and 
10 subunits, gamma-gliadin and its B-precursor and Brassica juncea Bra j 1-E allergen. These ORFs 
are downstream of the metallothionein-like (MTL) promoter transcribing the mCry3A coding 
sequence, but they are in a different reading frame and they do not contain a start codon, therefore 
their expression is highly unlikely. ORF MIR604_insert_2014_367 shows similarity to Bacillus lentus 
subtilisin savinase. This ORF is located on the reverse strand of the intended coding sequences, it has 
no promoter upstream and it has no start codon; therefore, its expression is highly unlikely. 
3.3. GA21 
An ORF, which is present at four locations in the insert due to internal repetitions, shows similarity to 
ragweed homologue of Art v 1 precursor allergen. This ORF is located on the reverse strand of the 
mepsps coding sequence and it has no promoter upstream; therefore, its expression is highly unlikely. 
Searches for eight-amino-acid-long exact matches to known allergens revealed that the newly 
expressed phosphomannose isomerase (PMI) proteins in MIR162 and in MIR604 show similarity to α-
parvalbumin allergen, and an ORF in event MIR162, which is located in an alternative frame 
compared with the Vip3Aa20 protein, shows similarity to the rAsp f9 allergen from Aspergillus 
fumigatus. All of these matches have already been assessed by the EFSA GMO Panel and no safety 
issues were identified (EFSA, 2009b; EFSA GMO Panel, 2012a). 
Based on the above information, the EFSA GMO Panel considers that its previous conclusions on the 
safety of the single maize events remain valid. 
4. Risk assessment of maize Bt11 × MIR162 × MIR604 × GA21 
4.1. Molecular characterisation 
Possible interactions between the known biological functions conferred by the individual insert and 
interactions that would affect protein expression level are considered. 
4.1.1. Genetic elements and their biological functions 
Maize Bt11, MIR162, MIR604 and GA21 are combined by conventional crossing to produce the four-
event stack maize Bt11 × MIR162 × MIR604 × GA21. The structure of the inserts introduced into the 
four-event stack maize is described in detail in the EFSA scientific opinions and no new genetic 
                                                     
13 Additional information: 3/7/2015. 
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modifications were involved. Genetic elements in the expression cassettes of the single events are 
summarised in Table 3. 
Table 3:  Genetic elements in the expression cassettes of events stacked in maize 
Bt11 × MIR162 × MIR604 × GA21 
Event Promoter 5' UTR transit peptide Coding region Terminator 
Bt11 35S 
(CaMV) 
IVS6 
(Zea mays) 
No cry1Ab 
(a)
 
(Bacillus 
thuringiensis) 
nos 
(Agrobacterium 
tumefaciens) 
35S 
(CaMV) 
IVS2 
(Z. mays) 
No pat 
(a)
 
(Streptomyces 
viridochromogenes) 
nos 
(A. tumefaciens) 
MIR162 ZmUbiInt 
(Z. mays) 
– No vip3Aa20 (a) 
(B. thuringiensis) 
35S 
(CaMV) 
ZmUbiInt 
(Z. mays) 
– No pmi 
(Escherichia coli) 
nos 
(A. tumefaciens) 
MIR604 MTL 
(Z. mays) 
– No mcry3A (a) 
(B. thuringiensis) 
nos 
(A. tumefaciens) 
ZmUbiInt 
(Z. mays) 
– No pmi 
(E. coli) 
nos 
(A. tumefaciens) 
GA21 Actin 1 
(Oryza sativa) 
Actin 1 
(O. sativa) 
OTP 
(Helianthus 
annuus) 
mepsps 
(Z. mays) 
nos 
(A. tumefaciens) 
(a): Codon optimised for expression in plants. 
–, when no element was specifically introduced to optimise expression; OTP, optimised transit peptide; UTR, untranslated 
region. 
There are seven newly expressed proteins in the four-event stack maize: three insecticidal proteins and 
four enzymes. Biological functions and intended effects conferred by these are summarised in Table 4. 
Table 4:  Biological functions and intended effects related to events stacked in maize 
Bt11 × MIR162 × MIR604 × GA21 
Event Protein Function in donor organism Intended effects 
Bt11 Cry1Ab Donor organism: B. thuringiensis var. 
kurstaki HD-1. B. thuringiensis is an 
insect pathogen; its insecticidal activity 
is attributed to the expression of crystal 
protein (cry) genes (Schnepf et al., 1998) 
Event Bt11 expresses a truncated 
version of the Cry1Ab protein. 
Cry1Ab is a protein toxic to certain 
lepidopteran larvae feeding on 
maize 
PAT Donor organism: S. viridochromogenes 
Tü494 phosphinothricin-
acetyltransferase (PAT) enzyme 
acetylates L-glufosinate-ammonium and 
thereby confers tolerance to 
phosphinothricin-based herbicides 
(Wohlleben et al., 1988) 
Expression of PAT in maize Bt11 
confers tolerance to glufosinate 
ammonium-based herbicides 
MIR162 Vip3Aa20 Donor organism: B. thuringiensis strain 
AB88 (Estruch et al., 1996). In addition 
to Cry proteins, B. thuringiensis also 
produces insecticidal proteins during its 
vegetative growth stage. These are 
referred to as vegetative insecticidal 
proteins (Fang et al., 2007) 
Event MIR162 expresses a 
modified version of the B. 
thuringiensis vip3Aa1 gene, and 
encodes Vip3Aa20, a protein toxic 
to certain lepidopteran larvae 
feeding on maize 
PMI 
(MIR162) 
Donor organism: E. coli. PMI catalyses 
the isomerisation of mannose-6-
phosphate to fructose-6-phosphate and 
plays a role in the metabolism of 
mannose (Markovitz et al., 1967) 
PMI (MIR162) is used as a 
selectable marker in maize 
MIR162. Mannose normally 
inhibits root growth, respiration and 
germination. Transformed cells 
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Event Protein Function in donor organism Intended effects 
expressing PMI are able to utilise 
mannose as a carbon source 
(Negrotto et al., 2000). PMI 
(MIR162) differs from PMI 
(MIR604) at two amino acid 
positions
14
 
MIR604 mCry3A Donor organism: B. thuringiensis subsp. 
tenebrionis (Sekar et al., 1987). B. 
thuringiensis is an insect pathogen; its 
insecticidal activity is attributed to the 
expression of crystal protein (cry) genes 
(Schnepf et al., 1998) 
The N-terminal 48 amino acid 
residues of the native Cry3A 
protein were deleted. In addition, a 
cathepsin-G protease recognition 
site was introduced for enhanced 
efficiency towards target pests 
(Chen and Stacy, 2003). Cry3A is a 
protein toxic to certain coleopteran 
larvae feeding on maize 
PMI 
(MIR604) 
Donor organism: E. coli. PMI catalyses 
the isomerisation of mannose-6-
phosphate to fructose-6-phosphate and 
plays a role in the metabolism of 
mannose (Markovitz et al., 1967) 
PMI (MIR604) is used as a 
selectable marker in maize 
MIR604. Mannose normally 
inhibits root growth, respiration and 
germination. Transformed cells 
expressing PMI are able to utilise 
mannose as a carbon source 
(Negrotto et al., 2000). PMI 
(MIR604) differs from PMI 
(MIR162) at two amino acid 
positions 
GA21 mEPSPS Donor organism: Z. mays. 
EPSPS is an enzyme involved in the 
shikimic acid pathway for aromatic 
amino acid biosynthesis in plants and 
microorganisms (Herrmann, 1995) 
The amino acid sequence of the 
maize EPSPS enzyme was modified 
to render the maize tolerant to 
glyphosate. Expression of mEPSPS 
confers tolerance to glyphosate-
based herbicides (Lebrun et al., 
2003) 
4.1.2. Integrity of the events in the four-event stack maize 
The genetic stability of the inserted DNA over multiple generations in the four single maize events 
was demonstrated previously (EFSA, 2005, 2007b, 2009a, b; EFSA GMO Panel, 2012a, b). Integrity 
of these events was demonstrated in the four-event stack maize
15
 by Southern analyses in an F1 
generation representative of the commercial seed production. 
4.1.3. Information on the expression of the inserts16 
Plants were grown at a single location (five replicate blocks) under field conditions in 2006 in USA
17
. 
The levels of Cry1Ab, PAT, Vip3Aa20, mCry3A, PMI and mEPSPS proteins in the four-event stack 
maize and the four single events were quantified by enzyme-linked immunosorbent assay (ELISA). 
Protein levels were determined in leaves (whorl and anthesis stages), root (whorl and anthesis stages), 
pollen (anthesis stage), grain (physiological maturity and senescence stages) and whole plant (anthesis, 
physiological maturity and senescence stages). Data on grain at physiological maturity are reported 
and discussed below (Table 5). Due to the high similarity between the PMI in maize MIR162and the 
PMI in maize MIR604, the antibodies used in ELISA recognised both proteins. Therefore, it was not 
possible to distinguish between the PMI expressed by event MIR162 and by MIR164 in the four-event 
stack. The level of PMI observed in the four-event stack maize is equivalent to the sum of the PMI 
levels observed in the single events. As PMI levels may have an effect on carbohydrate metabolism, 
                                                     
14 Dossier: Part I-Section D2(d). 
15 Dossier: Part I—Section D5 and Appendix 2. 
16 Dossier: Part I—Section D3. 
17 Dossier: Part I—Appendix 7. 
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the possible effects of PMI levels in the four-event stack maize are addressed in Section 4.2.3. 
Cry1Ab, PAT, Vip3Aa20, mCry3A and mEPSPS protein levels in the four-event stack maize were 
similar to the corresponding levels in the single maize events
18
 (see Table 5 for protein levels in grain). 
Table 5:  Means and ranges of protein levels (μg/g dry weight) in grain at physiological maturity 
from the single event maize Bt11, MIR162, MIR604, GA21 and the four-event stack maize 
Protein 
Bt11 x MIR162 x 
MIR604 x GA21 
Bt11 MIR162 MIR604 GA21 
Cry1Ab 
1.57 
(1.15 – 2.52) 
1.78 
(1.19 – 2.31) 
– – – 
PAT < LOD < LOD – – – 
Vip3Aa20 
140 
(89.7 – 165) 
– 
124 
(54.2 – 166) 
– – 
mCry3A 
0.62 
(0.40 – 0.77) 
– – 
0.72 
(0.19 – 1.11) 
– 
PMI 
(a)
 
5.18 
(3.38 – 6.54) 
– 
2.48 
(1.08 – 3.16) 
– – 
PMI 
(b)
 
4.74 
(1.19 – 5.94) 
– – 
2.33 
(1.55 – 2.99) 
– 
mEPSPS 
5.92 
(2.99 – 7.69) 
– – – 
5.34 
(3.62 – 7.61) 
(a): The reference standard for this ELISA was purified PMI (MIR162) protein. 
(b): The reference standard for this ELISA was purified PMI (MIR604) protein. 
–, not assayed; LOD, limit of detection. 
4.1.4. Conclusion 
The molecular data establish that the transformation events stacked in maize 
Bt11 × MIR162 × MIR604 × GA21 have the same molecular properties and characteristics as the 
single transformation events. Protein expression analyses showed that the levels of the newly 
expressed proteins are similar in the four-event stack and the single events, with the exception of PMI. 
Comparison of the levels of the newly expressed proteins between the four-event stack and each of the 
single events did not reveal an interaction that would affect protein expression level. 
Based on known mode of action of the newly expressed proteins, interaction between the Vip and Cry 
proteins in susceptible insects cannot be excluded (Bergamasco et al., 2013). Potential interactions are 
further assessed for their safety implications to human and animals in Section 4.3, and to the 
environment in Section 4.4. 
4.2. Comparative analyses 
4.2.1. Choice of comparator and production of material for the comparative assessment 
Two comparative field studies were performed, one for agronomic and phenotypic characterisation 
and one for compositional analysis. 
For the analysis of agronomic and phenotypic characteristics, the four-event stack maize and its 
conventional counterpart were grown in 10 locations in the USA in 2006
19
. The conventional 
counterpart was maize NP2673/NP2171, which had a genetic background similar to that of the four-
event stack maize as indicated by their pedigrees
20
. At each location, the two types of material were 
grown in different plots within replicated blocks (five blocks/location) according to a randomised 
complete block design. Maintenance pesticide treatment was applied to all maize materials according 
                                                     
18 Dossier: Part I—Appendix 7. 
19 Brookings, SD; Gaylord, MN; Janesville, WI; Maxwell, IA; Monroeville, IN; Seward, NE; El Paso, IL; Bloomington, IL ; 
Sadorus, IL ; Mackinaw, IL. 
20 Dossier: Part I—Section D7 and Appendix 10. 
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to the need at each site. No treatments of the four-event stack maize with the intended herbicides were 
included in the study. This experimental design allows a direct comparison between the four-event 
stack maize and its conventional counterpart in the presence of maintenance herbicides. 
For the compositional analysis of forage and grain derived from the four-event stack maize and the 
conventional counterpart (maize NP2673/NP2171) were grown in six locations in the USA in 2006
21
. 
At each location these materials were grown in different plots within replicated blocks (three 
blocks/location) according to a randomised complete block design. Maintenance pesticide treatment 
was applied to all maize materials according to the local requirement. All plots with the four-event 
stack maize were treated with glyphosate- and glufosinate-ammonium-based herbicides on top of 
maintenance pesticides. This experimental design does not allow the effects of the genetic 
modification to be distinguished from the herbicide treatments. 
4.2.2. Agronomic and phenotypic analysis 
Nineteen parameters related to crop physiology, morphology, development, yield and biotic stress 
were measured
22
. Data collected for 10 of the 19 parameters were subject to an Analysis of Variance 
(ANOVA) across locations. The other parameters (i.e. % barren plants, % dropped ears, % emerged 
plants, early emergence vigour, late season intactness, leaf colour rating, late root lodging, % stalk 
lodging, grey leaf spot) were not subject to a formal statistical analysis because of the nature of the 
endpoints. 
In the across-site analysis, no difference was observed between the four-event stack maize and its 
conventional counterpart for 8 of the 10 agronomic and phenotypic parameters. Significant differences 
were observed for grain test weight (converted to standard 15.5 % moisture; 72.48 ± 0.39 kg/hl for the 
four-event stack maize vs. 73.75 ± 0.36 kg/hl for the conventional counterpart), and percentage grain 
moisture (17.6 ± 0.20 % vs. 18.30 ± 0.20 %). 
These significant differences are not considered relevant for human and animal health, but are further 
assessed for their potential environmental impact in Section 4.4. 
4.2.3. Compositional analysis 
Nine compositional parameters were analysed in forage and 56 in grain. These parameters were 
consistent with the Organisation for Economic Co-operation and Development (OECD) 
recommendation (OECD, 2002). Samples of forage and grain were analysed for proximates, fibre 
fractions and minerals. In addition, grain were analysed for starch, fatty acids, amino acids, additional 
minerals, pro-vitamin A and vitamins and secondary metabolites and antinutrients
23
. 
The grain parameters showing significant differences are shown in Table 6. The levels of these 
constituents were within the ranges observed in commercial non-GM maize reference varieties 
(Table 6). Based on the well-known biochemical roles and the characteristics of the affected 
parameters, and taking into account the magnitude of the observed differences, the EFSA GMO Panel 
considers that further assessment for potential impacts on human and animal health is not required. 
                                                     
21 Dossier: Part I—Section D7 and Appendix 13. 
22 Parameters analysed as agronomic and phenotypic traits: % barren plants, % dropped ears, % emerged plants, early 
emergence vigour, early growth, ear height, early root lodging, % grain moisture, plant population at harvest, heat units to 
50 % silking, heat units to 50 % pollen shed, late season intactness, leaf colour rating, late root lodging, plant height, % 
stalk lodging, grain test weight, grain yield, grey leaf spot.  
23 Measured in forage of maize Bt11 × MIR162 × MIR604 × GA21 and the conventional counterpart in the USA in 2006: 
Proximates (moisture, fat, ash, protein, carbohydrates (calculated)), fibre fractions (acid-detergent fibre, ADF; neutral-
detergent fibre, NDF) and minerals (calcium, phosphorus). Measured in grain of Bt11 × MIR162 × MIR604 × GA21 and 
the conventional counterpart in the USA in 2006: Proximates (moisture, fat, ash, protein, carbohydrates (calculated)); 
starch; fibre fractions (ADF, NDF, total dietary fibre (TDF)); minerals (calcium, phosphorus, potassium, sodium, iron, 
copper, magnesium, manganese, selenium and zinc); (pro-)vitamins (β-carotene (pro-A), thiamine (B1), riboflavin (B2), 
niacin (B3), pyridoxine (B6), folic acid (B9), α-tocopherol (E)); amino acids; fatty acids; and secondary metabolites and 
antinutrients (furfural, phytic acid, inositol, trypsin inhibitor, raffinose, ferulic acid and p-coumaric acid). 
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Table 6:  Constituents (estimated means) showing significant differences between grain parameters 
of maize Bt11 × MIR162 × MIR604 × GA21 and its conventional counterpart NP2673/NP2171 
Component 
Bt11 x MIR162 x 
MIR604 x GA21 
 
Conventional 
counterpart  
Reference ranges
(a)
 
Copper  
[mg/kg dw] 
1.41 1.22 1.17 – 16.6 
Potassium  
[mg/kg dw] 
3988 3780 3090 – 5030 
Stearic acid  
[% of total fatty acids] 
1.71 1.84 1.29 – 2.19 
Oleic acid  
[% of total fatty acids] 
26.05 27.14 19.2 – 29.4 
Linoleic acid  
[% of total fatty acids] 
55.75 54.46 51.3 – 62.7 
Eicosenoic acid  
[% of total fatty acids] 
0.230 0.241 0.214 – 0.353 
NDF  
[% dw] 
9.70 9.07 4.28 – 13.9 
Pyridoxine 
[mg/kg dw] 
0.0623 0.0728 0.0439 – 0.0981 
Thiamine 
[mg/kg dw] 
0.0433 0.0416 0.0226 – 0.0520 
(a): The range indicated is based on a field trial using eight hybrids of commercially available non-GM maize lines grown at 
six locations in the USA in 2009. 
dw, dry weight. 
No significant differences in the composition of forage were observed. 
4.2.4. Conclusion 
The EFSA GMO Panel concluded that the two differences identified (grain test weight and grain 
moisture) in the agronomic and phenotypic characteristics of maize 
Bt11 × MIR162 × MIR604 × GA21 under the tested conditions (treatment with maintenance 
pesticides only) and its conventional counterpart would not require further assessment regarding food 
and feed safety, but are further assessed for their potential environmental impact in Section 4.4. 
The EFSA GMO Panel concluded that none of differences identified in the composition of grain and 
forage obtained from maize Bt11 × MIR162 × MIR604 × GA21 necessitated further assessment 
regarding food and feed safety. 
4.3. Food and feed safety assessment 
4.3.1. Effect of processing24 
Based on the outcome of the comparative assessment, processing of the four-event stack maize into 
food and feed products is not expected to result in products being different from those of commercial 
non-GM maize varieties. 
4.3.2. Toxicology 
4.3.2.1. Toxicological assessment of newly expressed proteins25 
Seven proteins are newly expressed in various tissues of the four-event stack maize (Section 4.1.3). 
The EFSA GMO Panel has previously assessed these proteins individually in the context of the single 
events, and no safety concern was identified. 
                                                     
24 Dossier: Part I—Section D7.6. 
25 Additional information: 19/3/2013. 
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The expression levels of the newly expressed proteins in the four-event stack maize were similar to 
those of the single events with the exception of PMI. Total PMI levels were consistently higher in the 
tissues of the four-event stack maize than individual events. This could be expected, given the 
introduction of two copies of pmi gene. No PMI protein is detectable in conventional counterparts 
(below LOD or limit of quantification (LOQ)). Therefore, the fact that introduction of PMI activity in 
these single events did not result in changes of relevant endogenous compounds (i.e. sugars, sugar 
alcohols and sugar phosphates) compared with the conventional counterparts (EFSA, 2009b; EFSA 
GMO Panel, 2012a), indicates that these enzymes would also have no impact on carbohydrate 
metabolism in the four-event stack maize. 
The four enzymatic proteins (PAT, mEPSPS and two PMI proteins) act on unrelated substrates, the 
mEPSPS protein is targeted to a specific cellular compartment (plastids). The three insecticidal 
proteins (Cry1Ab, mCry3A and Vip3Aa20) act through cellular receptors found in target insect 
species (Lee et al., 2003, 2006). It is reported that the gastrointestinal tract of mammals, including 
humans, lacks specific high affinity Cry protein receptors (Noteborn et al., 1995; Kuiper, 2001; 
Hammond et al., 2013). None of the seven proteins possessed structural similarities with known toxins 
to animals and humans, or showed adverse effects in the available toxicological studies. On the basis 
of the biological properties of the individual newly expressed proteins, there is currently no 
expectation for possible interactions relevant to the food and feed safety assessment of the four-event 
stack maize Bt11 × MIR162 × MIR604 × GA21. 
4.3.2.2. Toxicological assessment of components other than newly expressed proteins 
The four-event stack maize did not show any compositional difference to its conventional counterpart 
that would require further assessment (Section 4.2.4). No further food and feed safety assessment of 
components other than newly expressed proteins is required. 
4.3.3. Animal studies with the food/feed derived from GM plants 
A 49-day feeding study using chickens for fattening (both sexes) was provided
26
. In this study, 540 
broilers (Ross, day-old) were randomly allocated into three diet treatment groups with 180 chicks per 
treatment (15 birds per sex per pen and 12 pens per treatment). The four-event stack maize was 
compared with its conventional counterpart and to a non-GM commercial variety (NC2007 maize). 
Grain receiving the same local agricultural management was harvested from the 2006 field trial (see 
Section 4.2.1 for details on field trial design). Before mixing the feed, the maize samples were 
analysed for proximates, amino acids and mycotoxins. The chickens were fed starter, grower and 
finisher diets containing 47–51 %, 54–58 % and 60–63 % of maize grain, respectively. The diets were 
adjusted according to the standards of the Dutch Central Feed Bureau (CVB, 2001, 2002) and the 
National Research Council (NRC, 1994). The concentrations of the newly expressed proteins were 
determined in the grain and diets by ELISA
27
. Feed and water were provided for ad libitum intake. 
Chickens were observed twice daily for clinical signs; any death was recorded. Body weight and feed 
intake were measured on day 1, 16, 35 and 49. At day-50 two birds per pen were taken for carcass 
evaluation (dressing percentage weight of thighs, breast, wings, drums and abdominal fat). A two-way 
ANOVA (diet and gender) was applied, using the pen as the experimental unit. Overall mortality was 
low (< 3 %) with no significant difference between the groups. No significant treatment × gender 
interaction was detected. Final body weight (average ca 3.06 kg), feed:gain ratio (average 1.74) and 
carcass characteristics did not show significant differences between groups. 
The EFSA GMO Panel concluded that this study did not detect unintended effects, and showed that 
the four-event stack maize is as nutritious as its conventional counterpart and the non-GM commercial 
variety. 
                                                     
26 Dossier: Part I—Appendix 30; Additional information: 10/12/2013 (spontaneous submission). 
27 Protein concentration (µg/kg of dry weight) measured in the maize grain, starter diet, growth diet and finisher diet are 
Cry1Ab: 1.55, 0.47, 0.59 and 0.64, respectively; PAT always below LOD, Vip3Aa20: 87.76, 6.71, 6.84 and 19.68, 
respectively; Cry3A 0.25, below LOD, below LOQ and below LOQ, respectively; PMI: 3.89, 0.64, 0.74 and 1.68, 
respectively; mEPSPS: 7.53, 0.96, 1.11 and 2.23, respectively. 
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4.3.4. Allergenicity 
For allergenicity assessment, a weight-of-evidence approach is followed, taking into account all of the 
information obtained on the newly expressed proteins, since no single piece of information or 
experimental method yields evidence to predict allergenicity (EFSA, 2006; Codex Alimentarius, 2009; 
EFSA GMO Panel, 2011a). In addition, when known functional aspects of the newly expressed 
protein or structural similarity to known adjuvants may indicate an adjuvant activity, the possible role 
of these proteins as adjuvants is considered (EFSA GMO Panel, 2011a). When newly expressed 
proteins with a potential adjuvant activity are expressed together, possible interactions increasing 
adjuvanticity and impacting the allergenicity of the GM crop are assessed. 
4.3.4.1. Assessment of allergenicity of the newly expressed proteins 
For allergenicity, the EFSA GMO Panel has previously evaluated the safety of the Cry1Ab, mCry3A, 
Vip3Aa20, PAT, EPSPS and PMI proteins individually, and no concerns on allergenicity were 
identified in the context of the applications assessed (see EFSA scientific opinions listed in Table 2). 
No new information on allergenicity of the single events that might change the previous conclusions 
of the EFSA GMO Panel has become available. Based on current knowledge and since none of the 
newly expressed proteins showed allergenicity, no concerns regarding the mixture of these newly 
expressed proteins in the four-event stack maize affecting allergenicity are expected. 
For adjuvanticity, possible interactions between the newly expressed proteins increasing adjuvanticity 
and thereby potentially impacting on the allergenicity of a GM crop were considered. Bt proteins have 
been suggested to possess adjuvant activity, based on animal studies on Cry1Ac (e.g. Vázquez-Padrón 
et al., 1999; Moreno-Fierros et al., 2003; Rojas-Hernandez et al., 2004). However, at present, there is 
no evidence for Bt protein adjuvanticity of safety concern from the GM plants assessed so far by the 
EFSA GMO Panel (EFSA, 2009c; EFSA scientific opinions listed in Table 2). The levels of Bt 
proteins in this four-event stack maize are similar to those in the single maize events (Table 5). In 
addition, there is no information available on the structure or function of the individual newly 
expressed proteins that would suggest an adverse adjuvant effect of their mixture in the four-event 
stack maize, having also considered the lack of indications of adverse adjuvanticity of each individual 
protein in the single maize events. From the limited experimental evidence available, the EFSA GMO 
Panel did not find indications that the mixture of the Bt proteins in this four-event stack maize might 
act as adjuvants with the potential to enhance a specific IgE response and to favour the development of 
an allergic reaction. 
4.3.4.2. Assessment of allergenicity of the whole GM plant 
The EFSA GMO Panel regularly reviews the available publications on food allergy to maize (e.g. 
EFSA GMO Panel, 2013). However, to date, maize has not been considered to be a common 
allergenic food
28
 (OECD, 2002). Therefore, the EFSA GMO Panel did not request experimental data 
to analyse the allergen repertoire of GM maize. 
In the context of the present application and considering the data from the molecular characterisation, 
the compositional analysis and the assessment of the newly expressed proteins (see Sections 4.1 and 
4.2), the EFSA GMO Panel identified no indications of safety concern regarding the overall 
allergenicity of the four-event stack maize. 
4.3.5. Nutritional assessment of GM food/feed 
The intended trait of maize Bt11 × MIR162 × MIR604 × GA21 is herbicide tolerance and insecticide 
resistance, with no intention to alter the nutritional parameters. Comparison of the composition of 
maize Bt11 × MIR162 × MIR604 × GA21 with its conventional counterpart did not identify 
differences that would require a safety assessment (Section 4.2.4). From these data, the nutritional 
characteristics of maize Bt11 × MIR162 × MIR604 × GA21-derived food and feed are not expected to 
                                                     
28 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to 
Directive 2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 
27.11.2007, p. 11–14. 
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differ from those of conventional maize varieties. This was confirmed by a feeding study in chickens 
for fattening (Section 4.3.3). 
4.3.6. Conclusion 
The newly expressed proteins in the four-event stack maize do not raise safety concerns for human and 
animal health, since no adverse effects in the available studies were observed, no structural similarities 
to known toxins were detected, and no interactions are predicted at functional level based on the 
known mode of action. In addition, rapid degradation of these proteins shown in in vitro digestibility 
tests suggested negligible exposure to mammalian digestive tracks by these newly expressed proteins. 
Similarly, the EFSA GMO Panel did not identify safety concerns regarding allergenicity or 
adjuvanticity with the mixture of newly expressed proteins in this four-event stack maize, or regarding 
the overall allergenicity of the four-event stack maize. The four-event stack maize is as nutritious as its 
conventional counterpart and a non-GM commercial variety. 
4.4. Environmental risk assessment 
The approach followed by the GMO Panel to assess possible interactions between individual events in 
the four-event stack maize is to consider the scope of the four-event stack maize, the modes of action 
of the introduced traits and the outcome of the molecular characterisation, as well as the comparative 
analysis. 
Considering the scope (which excludes cultivation) of the four-event stack maize, the environmental 
risk assessment (ERA) is concerned mainly with (i) exposure of bacteria to recombinant DNA in the 
gastrointestinal tract of animal fed GM material and bacteria present in environments exposed to 
faecal material, and (ii) accidental release into the environment of viable grains of the four-event stack 
maize during transportation and processing. 
4.4.1. Potential unintended effects on plant fitness due to the genetic modification29 
Maize is highly domesticated, not winter hardy in many regions of Europe and generally unable to 
survive in the environment without appropriate management. The survival of maize plants outside 
cultivation areas is limited mainly by a combination of low competitiveness, absence of a dormancy 
phase and susceptibility to plant pathogens, herbivores and cold climate conditions. In fields, maize 
volunteers may arise under some environmental conditions (mild winters). Observations done in the 
field during harvesting indicate that grain may survive and overwinter in some regions, resulting in 
volunteers in subsequent crops. The occurrence of maize volunteers has been reported in Spain and 
other European regions (e.g. Gruber et al., 2008). However, maize volunteers have been shown to 
grow weakly and flower asynchronously with the maize crop (Palaudelmàs et al., 2009). 
As mentioned in Section 4.2.1, a field trial was carried out in the USA in 2006 to assess the agronomic 
and phenotypic performance of the four-event stack maize in comparison with its conventional 
counterpart
30
.
 
Significantly lower values were observed for two characteristics of the four-event stack 
maize, i.e. grain test weight and percentage grain moisture (Section 4.2.2). As no statistically 
significant differences were observed for those agronomic and phenotypic characteristics, which may 
affect fitness characteristics of the four-event stack maize, the EFSA GMO Panel concludes that these 
differences do not indicate a change in fitness of the four-event stack maize that would raise any 
relevant environmental safety concern. 
In addition to the data presented by the applicant, the EFSA GMO Panel is not aware of any scientific 
report of increased spread and establishment of the four-event stack maize or maize with comparable 
properties or of any change in survival capacity, including overwintering
31
. 
                                                     
29 Dossier: Part I—Section D7.4, D9.1 and Appendix 34. 
30 Dossier: Part I—Section D7.1, D7.4 and Appendix 10; Additional information : 25/03/2013. 
31 Dossier: Part I—Section D6 and Appendix 10. 
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The EFSA GMO Panel considers that the inserted traits did not change the general characteristics of 
maize in the four-event stack maize. 
Considering the scope of the four-event stack maize, the introduced traits, the outcome of the 
molecular characterisation, as well as the comparative analysis, and the poor ability of maize to 
survive outside cultivated land, the EFSA GMO Panel concludes that the four-event stack maize does 
not indicate an increased fitness potential compared with its conventional counterpart, if there was 
accidental release of viable GM maize grains into the environment. 
4.4.2. Potential for gene transfer32 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 
either horizontal gene transfer of DNA or vertical gene flow via grain dispersal and cross-pollination. 
4.4.3. Plant-to-bacteria gene transfer 
The potential for horizontal gene transfer of the recombinant DNA of the four single events and of the 
four already evaluated stacks to bacteria was assessed in previous opinions (see EFSA scientific 
opinions listed in Table 2). No concern as a result of an unlikely, but theoretically possible, horizontal 
gene transfer of the recombinant genes to bacteria in the gut or other receiving environments was 
identified. Synergistic effects of the recombinant genes in increasing the likelihood for horizontal gene 
transfer, for instance combinations of recombinogenic sequences, were not identified. Therefore, the 
EFSA GMO Panel concludes that, in the context of its scope, the unlikely, but theoretically possible, 
horizontal transfer of recombinant genes from this four-event stack maize to bacteria do not raise any 
environmental safety concern. 
4.4.4. Plant-to-plant gene transfer 
Considering the scope of the four-event stack maize and the biology of maize, a possible pathway to 
harm pertains to the potential of occasional feral GM maize plants originating from accidental spillage 
of imported grains to cause adverse environmental effects through the acquisition of recombinant 
DNA by sexually cross-compatible plants. As pointed out above (Section 4.4.1), occurrence of feral 
GM maize is expected to be limited. 
The extent of cross-pollination to other maize varieties will mainly depend on the scale of accidental 
release during transportation and processing and on successful establishment and subsequent 
flowering of the GM maize plant. For maize, any vertical gene transfer is limited to other Z. mays 
plants as populations of sexually compatible wild relatives of maize are not known in Europe 
(Eastham and Sweet, 2002; OECD, 2003). 
The flowering of occasional feral GM maize plants originating from accidental release during 
transportation and processing is unlikely to disperse significant amounts of GM maize pollen to other 
maize plants. Field observations performed on maize volunteers after GM maize cultivation in Spain 
revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that cross-
pollinated neighbouring plants at only low levels (Palaudelmàs et al., 2009). Thus, the likelihood of 
cross-pollination between cultivated maize and the occasional feral maize plants resulting from grain 
spillage is considered to be extremely low. 
In conclusion, considering the scope of the four-event stack maize, the mode of action of the 
introduced traits, the outcome of the molecular characterisation, as well as the comparative analysis, 
and the poor ability of maize to survive outside cultivated land, the EFSA GMO Panel is of the 
opinion that the likelihood of unintended environmental effects as a consequence of spread of genes 
from this GM maize in Europe will not differ from that of conventional maize varieties, even in the 
case of treatment with the intended herbicides. 
                                                     
32 Dossier: Part I—Section D6 and Appendix 34. 
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4.4.5. Interactions of the GM plant and target organisms33 
Interaction between the Vip and Cry proteins in susceptible insects cannot be excluded (Bergamasco et 
al., 2013). However, considering the scope (which excludes cultivation) of the four-event stack maize, 
and the low level of exposure to the environment, potential interactions of the GM maize with target 
organisms were not considered a relevant issue by the EFSA GMO Panel. 
4.4.6. Interactions of the GM plant with non-target organisms34 
Considering the scope (which excludes cultivation) of the four-event stack maize, and the low level of 
exposure to the environment, potential interactions of GM maize plants arising from spillage of 
imported grains with non-target organisms were not considered a relevant issue by the EFSA GMO 
Panel. The EFSA GMO Panel evaluated whether the Cry1Ab, Vip3Aa20 and mCry3A proteins might 
potentially affect non-target organisms by entering the environment through faecal material of animals 
fed the four-event stack maize. Cry proteins are degraded by enzymatic activity in the gastrointestinal 
tract, meaning that only a very low amount of these proteins would remain intact to pass out in faeces. 
This was demonstrated for Cry1Ab (Einspanier et al., 2004; Lutz et al., 2005, 2006; Wiedemann et al., 
2006; Guertler et al., 2008; Paul et al., 2010). Further degradation of the protein in the manure and 
faeces would take place because of microbiological proteolytic activity. In addition, there will be 
further degradation of Cry proteins in soil reducing the possibility for exposure of potentially sensitive 
non-target organisms. Data on degradation of Vip proteins are more limited. While proteins, including 
insecticidal Bt-proteins, may bind to clay minerals and humic substances in soil, thereby reducing their 
availability to microorganisms for degradation, there are no indications of persistence and 
accumulation of these proteins from GM crops in soil (reviewed by Icoz and Stotzky, 2008). The 
EFSA GMO Panel is not aware of evidence of released Bt-proteins causing significant negative effects 
on soil microorganisms. 
Considering the scope of the four-event stack maize, it can be concluded that the exposure of 
potentially sensitive non-target organisms to the mCry3A, Cry1Ab and Vip3Aa20 proteins expressed 
in the four-event stack maize is likely to be very low and of no biological relevance. 
4.4.7. Interactions with the abiotic environment and on biogeochemical cycles 
Considering the scope of the four-event stack maize (which exclude cultivation), and the low level of 
exposure to the environment, potential interactions with the abiotic environment and biogeochemical 
cycles were not considered a relevant issue by the EFSA GMO Panel. 
4.4.8. Conclusion 
The EFSA GMO Panel concludes that the four-event stack maize does not indicate an increased 
fitness potential compared with its conventional counterpart, if there was accidental release of viable 
GM maize grains into the environment. Considering the scope of the GM maize, interactions with the 
biotic and abiotic environment were not considered to be a relevant issue. Risks associated with an 
unlikely but theoretically possible horizontal gene transfer of recombinant DNA from the four-event 
stack maize to bacteria have not been identified. 
Therefore, considering the introduced traits and the outcome of the comparative analysis, the routes of 
exposure and the limited exposure levels, the EFSA GMO Panel concluded that this four-event stack 
maize would not raise safety concerns in the event of accidental release of viable GM maize grains 
into the environment, irrespective of possible interactions between the individual events within this 
four-event stack maize. 
                                                     
33 Dossier: Part I—Section D9.4 and Additional information: 25/03/2013. 
34 Dossier: Part I—Section D9.5. 
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4.5. Conclusion on maize Bt11 × MIR162 × MIR604 × GA21 
The combination of maize events Bt11, MIR162, MIR604 and GA21 in the four-event stack maize 
does not raise issues relating to molecular, agronomic, phenotypic or compositional characteristics that 
would require further assessment. 
The newly expressed proteins in the four-event stack maize do not raise safety concerns for human and 
animal health and the environment, in light of the scope of this application. 
No indications of interactions between the events based on the biological functions of the newly 
expressed proteins that would raise a safety issue were identified. Comparison of the levels of the 
newly expressed proteins between the four-event stack and each of the single events did not reveal an 
interaction that manifests at protein expression level. 
5. Risk assessment of the subcombinations 
The risk assessment of the 10 subcombinations (Table 1) takes as its starting point the results of the 
assessment of the single events, the data generated for the four-event stack maize and all the additional 
data available for the subcombinations. 
The EFSA GMO Panel assessed to what extent a combination of any of these events resulting in 
stacks with fewer than four events (see Table 1) could result in interactions manifesting at protein or 
trait expression level that were not observed in the four-event stack (e.g. because of masking). The 
potential for such interactions was addressed by investigating the known biological functions of the 
newly expressed proteins, and new data submitted. 
5.1. Subcombinations previously assessed 
There are four stacks that have been assessed previously by the EFSA GMO Panel: one three-event 
stack (maize Bt11 × MIR604 × GA21) and three two-event stacks (maize Bt11 × GA21, maize 
MIR604 × GA21 and maize Bt11 × MIR604). No safety concerns were identified (EFSA GMO Panel, 
2009, 2010a, b, c). For the three-event stack Bt11 × MIR604 × GA21, the applicant provided 
additional data
35
. 
5.1.1. Subcombinations with no new data 
No new scientific information regarding the three two-event stacks was retrieved in a literature search 
covering the period since the publication of the scientific opinions
 36
. Consequently, the EFSA GMO 
Panel considers that its previous conclusions on these stacks remain valid (EFSA GMO Panel, 2009, 
2010a, b). 
5.1.2. Subcombination with new data 
The EFSA GMO Panel assessed the additional information pertaining to the triple-event stack maize 
Bt11 × MIR604 × GA21
37,38
. 
5.1.2.1. Expression of the inserts 
Protein expression data supporting the previous EFSA assessment derive from field trials carried out 
in the USA in 2006 indicated that the levels of proteins in the stack are similar to levels in plants 
containing the single maize events. 
Additional protein expression data have been supplied for maize Bt11 × MIR604 × GA21 derived 
from field trials carried out in Romania and Spain in 2008, in which no glyphosate- or glufosinate-
                                                     
35 Additional information: 18/2/2014. 
36 Additional information: 10/10/2012 and 14/10/2014. 
37 Additional information: 18/2/2014. 
38 Additional information: 18/2/2014. 
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ammonium-based herbicide treatment was applied
39
. Data were provided for leaves (whorl, anthesis 
and maturity stages), roots (whorl, anthesis and maturity stages), pollen (anthesis stage) and grain 
(maturity stage). In these studies, the levels of the Cry1Ab, PAT, mCry3A, PMI and mEPSPS in the 
three-event stack were compared with the corresponding levels in the single maize events. This 
comparison did not reveal an interaction that would affect protein expression level in a way that it 
would require further assessment. 
5.1.2.2. Comparative analysis 
Additional information from field trials for agronomic, phenotypic and compositional data were 
obtained for the three-event stack maize and its conventional counterpart grown in six locations in the 
EU (three in Spain and three in Romania) in 2008
40
. In addition, agronomic and phenotypic data were 
collected in 2009 at seven locations (two in the Czech Republic, two in Spain and three in Romania). 
For both trials, maize Bt11 × MIR604 × GA21 was treated with glyphosate- and glufosinate-
ammonium-based herbicides on top of the maintenance pesticides. 
No differences in agronomic and phenotypic data of maize Bt11 × MIR604 × GA21 and its 
conventional counterpart, requiring further assessment were identified, other than the significant 
differences observed for plant height. These differences are further assessed for their potential 
environmental impact in Section 5.2.1.3. 
Significant differences in grain composition were identified for 14 parameters; increased levels of 
ADF, TDF, thiamine, riboflavin, α-tocopherol, arachidic acid and inositol; decreased levels of zinc; 
palmitic, stearic, oleic, linoleic, linolenic and eicosenoic fatty acids. The mean levels fell within the 
ranges of conventional maize published in the literature or reported by OECD (2002). Therefore, none 
of the differences observed in the composition requires further assessment with regard to safety. 
No significant differences were identified in the composition of forage. 
5.1.2.3. Environmental risk assessment 
The across-site analysis of the 2009 field trials showed statistically significant difference in plant 
height. The observed differences were not consistent across sites. Moreover, in the across-site 
analysis, the observed differences showed a lower plant height of the triple-event stack maize 
compared with its conventional counterpart. 
Considering the scope of the triple-event stack maize, and available evidence and the poor ability of 
maize to survive outside cultivated land, the EFSA GMO Panel concludes that the triple-event stack 
maize does not indicate an increased fitness potential compared with its conventional counterpart. 
Considering the scope of the three-event stack maize, possible interactions between the events that 
may impact on the environment are not considered to be a safety issue. 
5.1.3. Conclusion on the subcombinations previously assessed 
No new scientific information regarding these four stacks was retrieved in a literature search covering 
the period since the publication of the scientific opinions. Moreover, the additional data available on 
protein expression, agronomic, phenotypic and compositional characteristics of maize Bt11 × 
MIR604 × GA21 confirmed the result of the previous assessment. Consequently, the EFSA GMO 
Panel considers that its previous conclusions on these stacks remain valid. 
5.2. Subcombinations not previously assessed 
There are six subcombinations that were not previously assessed by the EFSA GMO Panel. Data were 
provided for one three-event stack maize Bt11 × MIR162 × GA21, but not for the others (maize 
Bt11 × MIR162 × MIR604, MIR162 × MIR604 × GA21, Bt11 × MIR162, MIR162 × MIR604, 
MIR162 × GA21). 
                                                     
39 Additional information: 18/2/2014 (Appendices 8.1 and 8.2). 
40 Additional information: 18/2/2014 (Appendix 14.1). 
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5.2.1. Subcombination with data 
The EFSA GMO Panel assessed the additional information pertaining to the three-event stack maize 
Bt11 × MIR162 × GA21
41
. 
5.2.1.1. Expression of the inserts 
The levels of Cry1Ab, PAT, Vip3Aa20, PMI (MIR162) and mEPSPS proteins in maize 
Bt11 × MIR162 × GA21 were compared with the corresponding levels in single maize events
42
. Plants 
were grown at a single location (five replicated blocks) under field conditions in 2006 in USA. Protein 
levels were determined in leaves (whorl, anthesis and physiological maturity stages), root (whorl, 
anthesis and physiological maturity stages), pollen (anthesis stage), grain (physiological maturity 
stage) and whole plant (anthesis, physiological maturity and senescence stages). Data on grain at 
physiological maturity are reported in Table 7. Comparison of the levels of the newly expressed 
proteins did not reveal an interaction that would affect protein expression level in a way that it would 
require further assessment. 
Table 7:  Means and ranges of protein levels (μg/g dry weight) in grain at physiological maturity 
from maize Bt11, MIR162, GA21 and the three-event stack maize 
Event/protein Bt11 × MIR162 × GA21 Bt11 MIR162 GA21 
Cry1Ab 
6.79 
(4.85–10.6) 
6.91 
(4.35–10.7) 
– – 
PAT < LOD < LOD – – 
Vip3Aa20 
83.8 
(59.2–102) 
– 
83.8 
(56.4–108) 
– 
PMI (MIR162) 
1.77 
(1.21–2.61) 
– 
1.84 
(1.11–2.58) 
– 
mEPSPS 
6.76 
(3.53–8.57) 
– – 
6.57 
(5.35–8.76) 
–, Not assayed; LOD, limit of detection. 
5.2.1.2. Comparative analysis 
The applicant provided compositional data for maize Bt11 × MIR162 × GA21 and its conventional 
counterpart from the same field trials in the USA in 2006
43
. Significant differences across sites were 
observed for increased levels of carbohydrates and decreased levels of phosphorus in forage. In grain, 
significant differences were observed for increased levels of copper, beta-carotene, thiamine and 
nicotinamide, and decreased levels of pyridoxine in maize Bt11 × MIR162 × GA21; increased levels 
of all amino acids, except for methionine, lysine, tryptophan and cysteine, as well as decreased levels 
of stearic acid, oleic acid, and increased levels of phytic acid. Their mean levels fell within the ranges 
reported for maize in literature (e.g. OECD, 2002; Reynolds et al., 2005). Therefore, none of the 
differences observed in the composition requires further assessment with regard to safety. 
No data on agronomic and phenotypic characteristics on this three-event stack maize were provided. 
5.2.2. Subcombinations with no data 
Integrity of the inserts was demonstrated in the four-event stack (Bt11 × MIR162 × MIR604 × GA21, 
Section 4.1.2). This was confirmed by results from three two-event stacks (Bt11 × GA21, 
Bt11 × MIR604, MIR604 × GA21) and from two three-event stacks (Bt11 × MIR162 × GA21
44
 and 
                                                     
41 Additional information: 18/2/2014. 
42 Dossier: Part I—Appendix 8. 
43 Dossier: Part I—Appendix 14. 
44 Dossier: Part I—Section D5 and Appendix 3. 
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Bt11 × MIR604 × GA21). Therefore, the EFSA GMO Panel finds no reasons to expect the loss of 
integrity in any of the subcombinations. 
The levels of Cry1Ab, PAT, mCry3A, Vip3Aa20 and mEPSPS proteins in the grain from the four-
event stack (Bt11 × MIR162 × MIR604 × GA21, Section 4.1.3) fell in the ranges observed for the 
single maize events, with the exception of PMI, which is higher in the four-event stack where both 
MIR604 and MIR162 events are present. These results did not reveal an interaction that would affect 
protein expression level in a way that it would require further assessment. This was confirmed by 
results from three two-event stacks (Bt11 × GA21, Bt11 × MIR604, MIR604 × GA21) and from two 
three-event stacks (Bt11 × MIR162 × GA21
45
 and Bt11 × MIR604 × GA21
46
). The EFSA GMO Panel 
finds no reasons to expect a different outcome for any of the subcombinations. 
5.2.3. Conclusion on subcombinations not previously assessed 
No indication of interactions between the events based on biological functions of the newly expressed 
proteins that would raise a safety issue was identified in the four-event stack maize. In particular, there 
is no biological basis to suggest that the presence of one protein may mask or enhance the effects of 
the others. Consequently, there is no reason to expect such interactions between these proteins in the 
10 subcombinations involving fewer than four events. This conclusion is supported by data on genetic 
integrity and protein expression from the five stacks for which such data were available. 
It is not expected that any combination of the newly expressed proteins would impact on the gross 
composition and consequently the nutritional characteristics of the maize variety into which they are 
introduced. This was shown by the comparative analyses of the four-event stack maize and confirmed 
by the comparative analyses of five stacks with their conventional counterparts. 
Considering the scope of the application, the mode of action of the introduced traits, the data available 
for various stacks and the poor ability of maize to survive outside cultivated land, the EFSA GMO 
Panel is of the opinion that different combinations of these events would not raise environmental 
concerns. 
These six subcombinations are expected to be as safe as the four-event stack maize. 
6. Post-market monitoring 
6.1. Post-market monitoring of GM food/feed 
The EFSA GMO Panel considers that post-market monitoring of food/feed derived from maize 
Bt11 × MIR162 × MIR604 × GA21 or 10 subcombinations is not necessary, given the absence of 
safety concerns identified. 
6.2. Post-market environmental monitoring 
The objectives of a PMEM plan, according to Annex VII of Directive 2001/18/EC, are: (1) to confirm 
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or 
its use, in the ERA are correct and (2) to identify the occurrence of adverse effects of the GMO, or its 
use, on human health or the environment which were not anticipated in the ERA. 
Monitoring is also related to risk management, and thus a final adoption of the PMEM plan falls 
outside the mandate of the EFSA GMO Panel. However, the EFSA GMO Panel gives its opinion on 
the scientific quality of the PMEM plan provided by the applicant (EFSA GMO Panel, 2011b). 
As the ERA did not identify potential adverse environmental effects from the four-event stack maize 
(Section 4.4.6) and four of its stacks (EFSA GMO Panel, 2009, 2010a, b, c), no case-specific 
monitoring is required. 
                                                     
45 Dossier: Part I—Appendix 8. 
46 Additional information: 18/2/2014 (Appendices 8.1 and 8.2). 
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The PMEM plans proposed by the applicant for the four-event stack maize
47
 or the four already 
assessed stacks
48
 (EFSA GMO Panel, 2009, 2010a, b, c) include: (1) the description of a monitoring 
approach involving operators (federations involved in maize import and processing), reporting to 
applicants, via a centralised system, any observed adverse effect(s) of GMOs on human health and the 
environment, (2) a coordinating system established by EuropaBio for the collection of the information 
recorded by the various operators and (3) the use of networks of existing surveillance systems (Lecoq 
et al., 2007; Windels et al., 2008). The applicant proposes to submit a PMEM report on an annual 
basis. 
The EFSA GMO Panel is of the opinion that the scope of the PMEM plans provided by the applicant 
is in line with the scope of the four-event stack maize and the four already assessed stacks. The EFSA 
GMO Panel agrees with the reporting intervals proposed by the applicant in its PMEM plans. 
However, the PMEM plan submitted by the applicant for the four-event stack maize does not include 
any provision for the six stacks assessed in this opinion (Section 5.2). Therefore, the EFSA GMO 
Panel recommends the applicant update it accordingly, by following the same aforementioned 
methodology and reporting policy. 
OVERALL CONCLUSIONS AND RECOMMENDATIONS 
No new data on the single maize events Bt11, MIR162, MIR604 and GA21 that would lead to a 
modification of the original conclusions on their safety were identified. 
The combination of maize events Bt11, MIR162, MIR604 and GA21 in the four-event stack maize 
Bt11 × MIR162 × MIR604 × GA21 did not give rise to issues – relating to molecular, agronomic, 
phenotypic or compositional characteristics – regarding food and feed safety. 
The newly expressed proteins in the four-event stack maize did not raise concerns for human and 
animal health. The compositional data indicate that maize Bt11 × MIR162 × MIR604 × GA21 would 
be expected to deliver the same nutrition as its conventional counterpart. This was confirmed by the 
results of an animal feeding study in chickens for fattening. 
The EFSA GMO Panel considers that there is no reason to expect interactions that could impact on 
food and feed safety. No safety concerns are foreseen for any subcombinations of the individual 
events, including those not previously assessed by EFSA. 
Considering the introduced traits and the outcome of the comparative analysis, the routes of exposure 
and the limited exposure levels, the EFSA GMO Panel concluded that this four-event stack maize 
would not raise safety concerns in case of accidental release of viable GM maize grains into the 
environment, irrespective of possible interactions between the individual events within this four-event 
stack maize. Moreover, in the light of the scope of the application, the data available for various 
subcombinations and the poor ability of maize to survive outside cultivated land, the EFSA GMO 
Panel is of the opinion that any subcombinations of the individual events, including those not 
previously assessed by EFSA, would not raise environmental safety concerns. 
Post-market monitoring of food/feed derived from maize Bt11 × MIR162 × MIR604 × GA21 or the 10 
subcombinations is not considered necessary. 
The PMEM plan submitted by the applicant for the four-event stack maize does not include any 
provision for the six subcombinations that were not previously assessed. Therefore, the EFSA GMO 
Panel recommends the applicant to revise the plan accordingly. 
RECOMMENDATION 
The EFSA GMO  Panel did not find indication that the subcombinations, resulting from combination 
of any of the single events included in the four-stack, would raise safety concerns. However, for some 
                                                     
47 Dossier: Part I – Section D11 and Appendix 35. 
48 EFSA-GMO-UK-2007-48, EFSA-GMO-UK-2007-49, EFSA-GMO-UK-2007-50, EFSA-GMO-UK-2007-56. 
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subcombinations (Bt11 x MIR162 x MIR604, MIR162 x MIR604 x GA21, Bt11 x MIR162, MIR162 
x MIR604, MIR162 x GA21) that could be produced by conventional crossing through targeted 
breeding approaches, little or no specific data were submitted.  For these the EFSA GMO Panel has 
drawn conclusions on a weight-of-evidence approach, giving rise to uncertainties due to data gaps.  
 
In order to reduce these uncertainties and to confirm assumptions made for the assessment of these 
subcombinations, the EFSA GMO Panel recommends that the applicant collate relevant information, if 
these subcombinations were to be created via targeted breeding approaches and commercialised in the 
future. In this case, this information should focus on expression levels of the newly expressed proteins. 
CORRESPONDENCE 
1. Letter from the Competent Authority of Germany, received on 20 February 2009, concerning a 
request for placing on the market of maize Bt11 × MIR162 × MIR604 × GA21 in accordance with 
Regulation (EC) No 1829/2003. 
2. Acknowledgement letter, dated 4 March 2009, from EFSA to the Competent Authority of 
Germany. 
3. Letter from EFSA to applicant, dated 27 March 2009, requesting additional information under 
completeness check. 
4. Letter from applicant to EFSA, received on 19 May 2009, providing additional information under 
completeness check. 
5. Letter from EFSA to applicant, dated 3 June 2009, requesting additional information under 
completeness check. 
6. Letter from applicant to EFSA, received on 12 June 2009 then updated on 24 June 2009, providing 
additional information under completeness check. 
7. Letter from EFSA to applicant, dated 13 July 2009, delivering the ‘Statement of Validity’ for 
application EFSA-GMO-DE-2009-66, maize Bt11 × MIR162 × MIR604 × GA21 submitted by 
Syngenta under Regulation (EC) No 1829/2003. 
8. Letter from EFSA to applicant, dated 21 September 2009, requesting additional information and 
stopping the clock. 
9. Letter from applicant to EFSA, received on 21 December 2009, providing additional information. 
10. Letter from EFSA to applicant, dated 5 February 2010, requesting additional information. 
11. Letter from applicant to EFSA, received on 5 October 2010, providing additional information. 
12. Letter from EFSA to applicant, dated 17 March 2010, requesting additional information. 
13. Letter from applicant to EFSA, received on 3 June 2010, providing additional information. 
14. Letter from applicant to DG Health and Consumer Protection of the European Commission, dated 
14 June 2010, clarifying the scope of the application. 
15. Letter from EFSA to applicant, received on 15 September 2010, clarifying that “a risk assessment 
of the single events is a pre-requisite for the risk assessment of stacked events” and maintaining 
the clock stopped. 
16. Letter from EFSA to applicant, dated 21 January 2011, requesting additional information. 
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17. Letter from applicant to EFSA, received on 1 February 2012, providing additional information 
18. Letter from applicant to EFSA, dated 15 March 2012, clarifying the scope of the application. 
19. Letter from EFSA to applicant, dated 6 June 2012, with the adoption of a scientific opinion on 
maize MIR162, restarting the clock. 
20. Letter from EFSA to applicant, dated 6 June 2012, confirming the scope of the application. 
21. Letter from EFSA to applicant, dated 6 July 2012, requesting additional information. 
22. Letter from applicant to EFSA, received on 10 October 2012, providing additional information. 
23. Letter from EFSA to applicant, dated 7 December 2012, requesting additional information. 
24. Letter from applicant to EFSA, received on 19 March 2013, providing additional information. 
25. Letter from EFSA to applicant, dated 5 February 2013, requesting additional information. 
26. Letter from applicant to EFSA, received on 25 March 2013, providing additional information. 
27. Letter from applicant to EFSA, dated 8 July 2013, redefining the scope of the application. 
28. Letter from applicant copy to EFSA, received on 24 July 2013, justifying the scope redefinition. 
29. Letter from EFSA to the applicants, dated 27 September 2013, restarting the clock. 
30. Letter from applicant to EFSA, received on 10 December 2013, spontaneously providing 
additional information. 
31. Letter from EFSA to applicant, dated 5 February 2014, requesting additional information. 
32. Letter from applicant to EFSA, received on 18 February 2014, providing additional information. 
33. Letter from applicant to EFSA, received on 28 July 2014, spontaneously providing additional 
information. 
34. Letter from EFSA to applicant, dated 9 September 2014, requesting additional information. 
35. Letter from applicant to EFSA, received on 25 September 2014, providing additional information. 
36. Letter from EFSA to applicant, dated 16 September 2014, requesting additional information. 
37. Letter from applicant to EFSA, received on 15 October 2014, providing additional information 
38. Letter from EFSA to applicant, dated 24 October 2014, requesting additional information. 
39. Letter from applicant to EFSA, received on 3 July 2015, providing additional information. 
40. Letter from EFSA to applicant, dated 21 July 2015, spontaneously providing additional 
information. 
41. Letter from EFSA to applicant, dated 10 August 2015, spontaneously providing additional 
information. 
42. Letter from EFSA to applicant, dated 18 September 2015, requesting additional information. 
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43. Letter from applicant to EFSA, received on 24 September 2015, providing additional information. 
44. Letter from EFSA to the applicants, dated 23 October 2015, restarting the clock. 
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APPENDIX 
Appendix A.  Summary of experimental data provided in previously assessed applications  
Risk assessment area 
Maize events 
Bt11 MIR162 MIR604 GA21 Bt11 × GA21 Bt11 × MIR604 MIR604 × GA21 Bt11 × GA21 × MIR604 
Newly expressed proteins Cry1Ab, 
PAT
(a)
 
Vip3Aa20 
PMI
(a)
 
mCry3A, 
PMI
(a)
 
mEPSPS Cry1Ab, 
PAT
(a)
, 
mEPSPS, 
Cry1Ab, 
PAT
(a)
, 
mCry3A, 
PMI
(a)
 
mCry3A, PMI
(a)
, 
mEPSPS 
Cry1Ab, PAT
(a)
, 
mEPSPS, mCry3A, 
PMI
(a)
 
Molecular characterisation 
Transformation process and vector constructs         
Insert structure and flanking regions         
Bioinformatic searches         
Integrity and genetic stability of the insert(s)         
Protein expression         
Comparative assessment 
Field trials          
Agronomic and phenotypic characteristics          
Compositional analysis          
Food and feed safety 
Characterisation of the newly expressed 
protein(s) 
        
Heat stability         
Degradation in simulated digestive fluids         
Acute toxicity study with newly expressed 
proteins 
        
Repeated-dose toxicity study with newly 
expressed proteins 
             
Rodent feeding study with whole food and feed         
Feeding study in fast-growing animals (e.g., 
broiler) 
        
Feeding study in farm animals (e.g., calves, pig, 
cows, sheeps, etc) 
               
Environmental risk assessment 
Pollen viability         
Seed germination         
(a): Selectable markers, and PMI expressed in MIR162 differs from the one expressed in MIR604. 
, Data were generated for the event in question, blank cells indicate that no data were provided; , data not specific to the event in question, e.g. a subchronic toxicity study was performed with 
feed formulated from the Bt11 maize grain, but from another maize event expressing the Cry1Ab protein. 
